Travere Therapeutics (TVTX) Fundamental Analysis: Revenue, Earnings & Valuation

6.03 / 10

Outperform

Fundamental analysis rates TVTX as Outperform with a 6.03/10 score. Strengths include strong asset‑MV (0.53 weight), revenue‑MV (0.34), and low cost‑of‑sales ratio. Weak points are negative income‑tax ratio and low PB‑ROE, though overall quality remains satisfactory.

Analysis Checks(8/10)

Revenue-MV

Value-1.13

Score3/3

Weight33.85%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value110.45

Score2/3

Weight1.80%

1M Return0.58%

Inventory turnover ratio

Value1.71

Score3/3

Weight-1.92%

1M Return-0.67%

Accounts receivable turnover ratio

Value9.15

Score2/3

Weight-1.90%

1M Return-0.65%

PB-ROE

Value4.54

Score0/3

Weight13.91%

1M Return3.80%

Income tax / Total profit (%)

Value-2.01

Score1/3

Weight-1.74%

1M Return-0.59%

Fixed assets turnover ratio

Value104.88

Score3/3

Weight2.53%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.15%

1M Return-0.73%

Cost of sales ratio (%)

Value2.11

Score3/3

Weight2.67%

1M Return0.79%

Asset-MV

Value-0.55

Score3/3

Weight52.95%

1M Return13.09%

Is TVTX undervalued or overvalued?

TVTX scores 6.03/10 on fundamentals and holds a Discounted valuation at present. Backed by its -29.38% ROE, -5.21% net margin, -98.39 P/E ratio, 21.89 P/B ratio, and 92.89% earnings growth, these metrics solidify its Outperform investment rating.